Yomiuri -- Domestic pharmaceutical companies are engaged in a drastic reorganization of their research departments to focus on developing specific medical solutions for targeted diseases, inspired by the organizational model of venture firms. The moves come amid concern over future profitability, as several patents for leading drugs are set to expire soon, and simply making current research departments bigger has not led to the breakthrough products that could sustain profit levels.
